Tim W Harrison
Overview
Explore the profile of Tim W Harrison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Louis R, Harrison T, Chanez P, Menzella F, Philteos G, Cosio B, et al.
J Allergy Clin Immunol Pract
. 2023 Mar;
11(6):1759-1770.e7.
PMID: 36948488
Background: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join...
2.
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
Busby J, Matthews J, Chaudhuri R, Pavord I, Hardman T, Arron J, et al.
Eur Respir J
. 2021 Sep;
59(4).
PMID: 34561291
Background: Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. Methods: We reviewed patient choice to...
3.
Canonica G, Harrison T, Chanez P, Menzella F, Louis R, Cosio B, et al.
Allergy
. 2021 May;
77(1):150-161.
PMID: 33978983
Background: Clinically meaningful improvement in the Sino-Nasal Outcome Test-22 (SNOT-22) was observed in patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated with benralizumab in the ANDHI trial. A...
4.
Martin M, Zain N, Hearson G, Rivett D, Koller G, Wooldridge D, et al.
PLoS One
. 2020 Dec;
15(12):e0244681.
PMID: 33378384
Background: Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, but evidence suggests a link between ICS usage and increased rates of respiratory infections. We assessed the composition of the...
5.
Harrison T, Chanez P, Menzella F, Canonica G, Louis R, Cosio B, et al.
Lancet Respir Med
. 2020 Dec;
9(3):260-274.
PMID: 33357499
Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms....
6.
Heaney L, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S, et al.
Lancet Respir Med
. 2020 Sep;
9(1):57-68.
PMID: 32916135
Background: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic...
7.
Martin M, Beasley R, Harrison T
Thorax
. 2020 Aug;
75(12):1119-1129.
PMID: 32839286
Asthma attacks (exacerbations) are common, accounting for over 90 000 UK hospital admissions per annum. They kill nearly 1500 people per year in the UK, have significant associated direct and...
8.
Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison T, et al.
Eur Respir J
. 2020 Jan;
55(1).
PMID: 31919194
No abstract available.
9.
10.
Martin M, Lee H, Clayton C, Pointon K, Soomro I, Shaw D, et al.
Respirology
. 2019 Feb;
24(6):558-565.
PMID: 30722097
Background And Objective: Adult patients with chronic productive cough of unknown cause are commonly seen in respiratory clinics. We have previously described a subgroup of these patients who have a...